UBS Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

UBS Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,430	Closed	-$56K	–	9919
2020 Q4	$56K	Sell	2,430 -65,731	-96%	-$833K	﹤0.01%	6092
2020 Q3	$694K	Sell	68,161 -4,727	-6%	-$63.4K	﹤0.01%	3915
2020 Q2	$1.09M	Sell	72,888 -1,652	-2%	-$25.4K	﹤0.01%	3440
2020 Q1	$908K	Sell	74,540 -2,224	-3%	-$35.4K	﹤0.01%	3438
2019 Q4	$1.22M	Buy	+76,764	New	+$979K	﹤0.01%	4024
2019 Q3	–	Sell	-10,485	Closed	-$119K	–	4006
2019 Q2	$138K	Buy	+10,485	New	+$153K	﹤0.01%	5160

UBS Group's PRVL Position: Q1 2021 in Review

UBS Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 2,430 shares — an estimated $56K sold.

UBS Group first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $1.22M in Q4 2019. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

UBS Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
UBS Group sold 2,430 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $56K.
UBS Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
UBS Group's Prevail Therapeutics Inc. Common Stock position peaked at $1.22M in Q4 2019.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.